Midatech Pharma Plc

Midatech Pharma Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Midatech Pharma (NASDAQ: BDRX ) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new research program. According to a filing with the Securities and Exchange Commission (SEC).

Why Is Midatech Pharma (BDRX) Stock Up 64% Today?

ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 27, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, is pleased to announce a new research programme coded MTD217 focusing on developing new therapeutic options for metastatic cancers with high unmet needs. Background Many cancers exhibit high levels of metabolic plasticity, i.e.

Midatech Pharma PLC Announces R&D Programme Focused on Leptomeningeal Disease

Share Consolidation, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIM ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 24, 2023 / Midatech Pharma PLC (AIM:MTPH)(Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that at the general meeting of the Company held earlier today (the "General Meeting"), all resolutions put to the Company's shareholders ("Shareholders") were duly passed. The full text of, inter alia, the resolutions proposed and passed at the General Meeting can be found in the Company's Shareholder Circular and Notice of General Meeting (the "Circular") which was published and posted to Shareholders on 7 March 2023 and is available on the Company's website at www.midatechpharma.com.

Midatech Pharma PLC Announces Results of General Meeting

ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 10, 2023 / Further to the announcement made on 8 March 2023 providing notice of a general meeting (the "GM") of the Company to be held on 24 March 2023, and the publication and despatch of a circular to shareholders containing notice of the resolutions to be considered at the GM (the "Notice") and form of proxy (the "Form of Proxy"), the Company announces the following corrections to certain typographical errors identified within the Notice and Form of Proxy

Midatech Pharma PLC Announces Further re: Notice of General Meeting

Proposed Share Consolidation, Authority to Allot Shares, Disapplication of Pre-Emption Rights, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIM ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 8, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces, further to the Company's announcements of 9 February and 15 February 2023, that a circular (the "Circular") and formal Notice of General Meeting was posted to shareholders yesterday and will be made available on the Company's website at: www.midatechpharma.com/investors/shareholder-information. The Circular contains details of, inter alia, the Company's proposed share consolidation, authority to allot ordinary shares and to disapply pre-emption rights, change of name, adoption of New Articles, and cancellation of the admission of the Company's ordinary shares to trading on AIM, all of which are subject to, inter alia, approval by shareholders at the General Meeting.

Midatech Pharma PLC Announces Posting of Circular and Notice of General Meeting

ABINGDON, UK / ACCESSWIRE / February 15, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces the closing of the Private Placement of 10,344,822 Units initially at an issue price of US$0.58 per Unit (further details of which were set out in the announcement of 9 February 2023). Each such Unit comprises either (i) one American Depository Share ("ADS"), one A Warrant and one and one-half B Warrants, or (ii) one Pre-Funded Warrant, one A Warrant and one and one-half B Warrants.

Midatech Pharma PLC Announces Closing of $6.0m Private Placement & Broker Change

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (THE "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES OF SECURITIES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY SECURITIES OF THE COMPANY.

Midatech Pharma PLC Announces Private Placement Raising US $6.0 million

ABINGDON, OXFORDSHIRE / ACCESSWIRE / February 3, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it received written notification (the "Notification Letter") from The NASDAQ Stock Market LLC ("NASDAQ"), dated 31 January 2023, stating that the Company is not in compliance with the minimum bid price requirement set forth in NASDAQ's rules for continued listing on The NASDAQ Capital Market. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

Midatech Pharma PLC Announces Receipt of NASDAQ Notice

Result of General Meeting Appointment of Specialist Business Advisory Firm - Quantuma ABINGDON, OXFORDSHIRE / ACCESSWIRE / January 23, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that at its General Meeting held at 10.00 a.m. today all ordinary resolutions were carried, but all other resolutions were not passed by shareholders, as set out in the table below.

Midatech Pharma PLC Announces Result of General Meeting

Planned Dose Escalation in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma ABINGDON, UK / ACCESSWIRE / January 12, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that following completion of one month of treatment with MTX-110 in the first patient, its Phase I study of MTX-110 in recurrent glioblastoma ("rGB") (NCT 05324501) will continue with a planned dose escalation following a positive recommendation from the study's Data Safety Monitoring Board ("DSMB"). The Phase I study, the MAGIC-G1 study, is an open-label, dose escalation study designed to assess the feasibility and safety of intermittent infusions of MTX-110 administered by convection enhanced delivery (CED) via implanted refillable pump and catheter.

Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, JAPAN AND THE REPUBLIC OF SOUTH AFRICA.

Midatech Pharma PLC Announces Closing of Offering, Revised Terms, AIM & Webinar

Midatech Pharma PLC (AIM:MTPH) fell another 13% to 3p on Wednesday, having now slashed its market valuation by half in the past five days. A day earlier, Midatech announced the proposed acquisition of Canada-listed Bioasis Technologies Inc for C$7.4mln (£4.4mln).

Midatech Pharma plc continues to plummet on news of London delisting

Midatech Pharma PLC Announces Proposed Acquisition of Bioasis Technologies Inc

First Patient Enrolled in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma ABINGDON, OXFORDSHIRE / ACCESSWIRE / November 14, 2022 / Midatech Pharma PLC (AIM:MTPH.L; Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce the enrolment of the first patient into its Phase 1 study of MTX110 in recurrent glioblastoma (rGB) (NCT 05324501) at the Preston Robert Tisch Brain Tumor Center at Duke University, USA. The Phase I study is an open-label, dose escalation study designed to assess the feasibility and safety of intermittent infusions of MTX110 administered by convection enhanced delivery (CED) via implanted refillable pump and catheter.

Midatech Pharma PLC - First Patient Enrolled in Phase 1 Study of MTX-110

ABINGDON, OXFORDSHIRE / ACCESSWIRE / October 18, 2022 / Midatech Pharma (AIM:MTPH)(NASDAQ:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announces that further to the Company's announcement on 14 April 2022, it has received written notification dated 10 October 2022 (the "Notification Letter") from The NASDAQ Stock Market LLC ("NASDAQ") that for 10 consecutive business days, from 26 September 2022 to 9 October 2022, the closing bid price of the Company's American Depositary Shares had been at $1.00 per share or greater and, accordingly, the Company has regained compliance with NASDAQ Listing Rule 5550(a)(2). For further information, please contact: Midatech Pharma PLC Stephen Stamp, CEO, CFOTel: +44 (0)29 20480 180 www.midatechpharma.com Strand Hanson Limited (Nominated and Financial Adviser) James Dance / Matthew Chandler / Rob Patrick Tel: +44 (0)20 7409 3494 IFC Advisory Limited (Financial PR and UK Investor Relations) Tim Metcalfe / Graham Herring Tel: +44 (0)20 3934 6630 Email: midatech@investor-focus.co.uk Edison Group (US Investor Relations) Alyssa Factor Tel: +1 (860) 573 9637 Email: afactor@edisongroup.com About Midatech Pharma PLC Midatech Pharma PLC (dual listed on LSE AIM:MTPH; and NASDAQ:MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines.

Midatech Pharma PLC Announces Receipt of NASDAQ Notification

ABINGDON, OXFORDSHIRE / ACCESSWIRE / September 14, 2022 / Midatech Pharma (AIM:MTPH)(Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announces a ratio change on its American Depositary Receipts ("ADR") from one (1) ADR representing five (5) ordinary shares, to the new ratio of one (1) ADR representing twenty-five (25) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be 26 September 2022.

Midatech Pharma PLC Announces ADR Ratio Change

ABINGDON, OXFORDSHIRE / ACCESSWIRE / September 14, 2022 / Midatech Pharma Plc (AIM:MTPH; NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces its unaudited interim results for the six months ended 30 June 2022 which will also be made available on the Company's website at www.midatechpharma.com. OPERATIONAL HIGHLIGHTS The Company announced the following in the six months ended 30 June 2022: Q-Sphera In January, an extension of its R&D collaboration with Janssen Pharmaceutica NV (Janssen) to focus on maximising drug loading and optimising in vitro duration of release for an undisclosed Janssen experimental molecule; In March, another R&D collaboration with Janssen on a second large molecule, also focused on maximising drug loading and optimising in vitro duration of release; MTX110 In June, granting by the FDA of Fast Track Designation for MTX110 in the treatment of recurrent glioblastoma (rGBM); and Also in June, granting of Orphan Medicine Designation for MTX110 for the treatment of glioma by the European Medicines Agency.

Midatech Pharma PLC Announces Interim Results for the Six Months to 30 June 2022

Midatech Pharma PLC (AIM:MTPH) is in demand after a positive European approval for a key product. The biotechnology company said that the European Medicines Agency had granted orphan medicinal product designation for its development programme of MTX110 for the treatment of glioma Midatech has been developing MTX110 for the treatment of recurrent glioblastoma ("rGBM") in adult patients and diffuse intrinsic pontine glioma ("DIPG") and medulloblastoma in paediatric patients.

Midatech Pharma boosted by European news on key product

Orphan Designation Granted by EMA to MTX110 Development for the Treatment of Glioma ABINGDON, NR / ACCESSWIRE / June 21, 2022 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that following the submission of an application to the European Medicines Agency ("EMA"), its development programme of MTX110 for the treatment of glioma has been granted Orphan Medicinal Product designation by the agency. Midatech has been developing MTX110 for the treatment of recurrent glioblastoma ("rGBM") in adult patients and diffuse intrinsic pontine glioma ("DIPG") and medulloblastoma in paediatric patients.

Midatech Pharma PLC Announces MTX110 Development for the Treatment of Glioma

ABINGDON, OXFORDSHIRE / ACCESSWIRE / June 20, 2022 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce the appointment of Dr Stephen Parker as a Director of the Company and Non-Executive Chairman of the Board with immediate effect. Stephen Parker has over 30 years' experience in leadership roles both in the healthcare industry and in advisory roles.

Midatech Pharma PLC Announces Directorate Change

ABINGDON, OXFORDSHIRE / ACCESSWIRE / June 10, 2022 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that investigators from Columbia University Irving Medical Center and New York-Presbyterian will present interim results from their ongoing Phase 1 study on Midatech's MTX110 in Diffuse Intrinsic Pontine Glioma ("DIPG") at The International Symposium on Pediatric Neuro-Oncology ("ISPNO 2022") that will take place on 12-15 June 2022 in Hamburg, Germany. The presentation is titled: "A Phase I study examining the feasibility of intermittent convection-enhanced delivery (CED) of MTX110 for the treatment of children with newly diagnosed diffuse midline gliomas.

Midatech Pharma PLC - MTX110 Study to be Presented at ISPNO 2022

ABINGDON, OXFORDSHIRE / ACCESSWIRE / June 10, 2022 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announces that Rolf Stahel, Chairman and non-executive director, intends to retire after the Company's Annual General Meeting on 20 June 2022 ("AGM"). It is expected that Dr. Stephen Parker will be appointed as non-executive Chairman of the Board, following the AGM.

Midatech Pharma PLC Announces Retirement of Chairman and Proposed New Chairman

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Midatech Pharma PLC's (NASDAQ: MTP) lead drug candidate MTX110 for the treatment of patients with recurrent glioblastoma (rGBM). The company is planning to begin recruitment in the phase 1 study evaluating MTX110.

Midatech Pharma's Shares Shoot Higher On FDA Fast Track Designation For Malignant Brain Tumor Drug

U.S.-listed shares of Midatech Pharma PLC ADR MTP, +0.03% MTPH, soared 35.7% in premarket trading on Wednesday after the company said the Food and Drug Administration granted Fast Track status to the treatment it's developing for recurrent glioblastoma, a fast-growing brain tumor. Midatech's stock is down 40.3% this year, while the S&P 500 SPX, -0.63% has declined 13.3%.

Midatech's investigational glioblastoma treatment gets Fast Track status

Fast Track Designation Granted to MTX110 Development for the Treatment of Recurrent Glioblastoma ABINGDON, OXFORDSHIRE / ACCESSWIRE / June 1, 2022 / Midatech Pharma PLC (AIM:MTPH.L); (NASDAQ:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that upon submitting an application to the U.S. Food and Drug Administration ("FDA"), its development programme of MTX110 for the treatment of recurrent glioblastoma ("rGBM") has been granted Fast Track designation by the agency. Fast Track is a process designed to facilitate the development and expedite the review of treatments for serious conditions and that potentially address unmet medical needs.

News for Midatech Pharma Plc Stock (MTP)